

ASX RELEASE | OSTEOPORE LIMITED

## OSTEOPORE TO DEVELOP IMPLANTS THAT ACCELERATE BONE REGENERATION

### Highlights:

- *Osteopore has received approximately US\$360,000 in non-dilutive grant funding to develop an alternative and improved implant that accelerates bone regeneration.*
- *The funding comes from the government of Chile's Scientific and Technological Development Support Fund (FONDEF), and the University of Chile.*
- *The research will focus on developing breakthrough materials and compounds that can be incorporated into Osteopore's implants to stimulate cell and tissue growth.*
- *If successful, the implants would be a world first and could improve surgical outcomes, reduce recovery time, and lower overall healthcare costs. Speeding up bone growth is widely considered the 'holy grail' of bone regeneration technology.*
- *The project forms part of the Osteopore's strategy to improve existing commercial products, refine the manufacturing process, and expand our portfolio of patents and trade secrets.*

**28 September 2022: Osteopore Limited** (ASX: OSX) ("Osteopore" or the "Company"), a revenue-generating manufacturer of regenerative implants that empower natural tissue regeneration, is pleased to announce it has received a US\$225,000 non-dilutive grant from the Government of Chile, to develop a novel 3D-printable implant that **accelerates** bone regeneration.

Currently, Osteopore's implants enable the **natural stages** of bone healing and are superior to other traditional bone regeneration procedures. However, by incorporating materials and compounds that speed up bone growth, a patients' recovery could be accelerated. If successful, this would be a world first breakthrough that places Osteopore at the forefront of technology development and would be considered the 'holy grail' of bone regeneration.

The grant was awarded to Osteopore from the Scientific and Technological Development Support Fund (FONDEF), a program that is part of the National System of Public Funds for Scientific and Technological Research in Chile. Established in 1991, FONDEF aims to advance development of innovative projects that can improve Chile's competitiveness and the quality of life of its population.

The project was presented to FONDEF by the Universidad de Chile (University of Chile), in association with Osteopore, and it was ranked 6th out of 111 projects granted. The University of Chile has also agreed to provide non-incremental expenses totalling US\$135,000 towards the project.

Osteopore Executive Chairman Mark Leong said: "We are extremely excited about this partnership, as it comes with non-dilutive funding and could see enormous potential commercial opportunities if successful. Developing materials that can speed up bone regeneration would have far reaching

positive clinical outcomes for patients globally, and we continue to see scientists and clinicians around the world take an interest in the Osteopore technology for this reason. We will continue to collaborate with industry stakeholders to improve our technology and develop new applications that improve patient care now and in the future.”

### **Project Synopsis:**

Osteopore products are made from polycaprolactone (PCL), a polymer that is extensively used in many US FDA approved devices. PCL is bio-resorbable, malleable, slow-degrading and possesses mechanical strength similar to trabecular bone. The rate of resorption of PCL is very much in tandem with the natural stages of bone healing, making it a predictable material for matching to the natural stage of bone healing.

In this study, Osteopore and its research partners aim to incorporate elements into our implants that further improve and stimulate cell and tissue growth. If successful, this will provide an alternative and improved version of Osteopore’s regenerative implants that could improve surgical outcomes, reduce recovery time, and lower overall healthcare costs.

The research will begin in October 2022 and will take place at the University of Chile. Osteopore and its research partners will now work towards confirming a formal research and development program, and will update the market as milestones are reached. IP ownership is to be discussed based on each party’s contributions to the said IP. At this point, terms have not been negotiated.

The project forms part of the Company’s strategy to improve existing commercial products, refine the manufacturing process, and expand our portfolio of patents and trade secrets.

*This announcement has been approved for release by the Board of Osteopore.*

For more information, please contact:

### **Mark Leong**

Executive Chairman

Osteopore Limited

+65 9011 7009

[Mark\\_Leong@osteopore.com](mailto:Mark_Leong@osteopore.com)

### **About Osteopore Limited**

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of products specifically engineered to facilitate natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants. Our 3D printer technology is not available in the market and unique to Osteopore.

## **Forward-Looking Statements**

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.